Pacidamycins are nucleosidyl-peptide antibiotics which have activity only against Pseudomonas aeruginosa. Their MICs for other organisms such as Enterobacteriaceae, Staphylococcus aureus, most Streptococci and other Pseudomonas species are > 100 iwg/ml. These compounds had no activity against erythromycin-susceptible Streptococci. The MICs for
aeruginosa ranged from 8 to 64^g/ml. The activity of these compounds was 1 to 2-fold less in serum than broth. Time-kill curves were performed using 4 and 8 times the MIC of pacidamycin 1. It was bactericidal against P. aeruginosa (3 log10 decrease in 4 to 6 hours). At 24 hours, resistant mutants were found in the cultures. The MICsof piperacillin and gentamicin for these mutants were the same as for the parent strain. The frequency of resistance to these compounds was<3.5x lO~6. The resistant mutants were stable after 10 transfers in antibiotic-free medium.The pacidamycins were inactive against P. aeruginosa in mouseprotection tests. After a single subcutaneous injection of25 mg/kg ofpacidamycin 1, the Cmaxwas approximately 50 jugjml and the serum half-life was 0.5 hour.
Pseudomonas aeruginosa infections are a problem to treat in spite of the availability of large numbers of antibiotics because of their intrinsic resistance and their ability to become resistant to new classes of antibacterial agents1}. Pacidamycins are a novel class of antibiotics which have been isolated from a screen designed to find antibiotics with activity against P. aeruginosa. The taxonomy of the producing culture, the fermentation, isolation and chemical structures of these compounds are described in the preceding manuscripts2>3). The biological activities of these compounds will be described in part at the 28th Intersci. Conf. on Antimicrob. Agents Chemother.4).
Materials and Methods

Antibiotics
The pacidamycins were isolated at Abbott Laboratories. The majority of the experiments were performed with pacidamycin 1 (A-68567), the alanine-tryptophan analog. Pacidamycins 2 (alaninephenylalanine analog), 3 (alanine-meta-tyrosine) and 5 (phenylalanine analog) were also tested when sufficient quantities were available
In Vitro Antibacterial Activity The bacterial strains used in this study were clinical isolates or cultures obtained from the American Type Culture Collection (ATCC, Rockville, Maryland, U.S.A.) which are maintained frozen in our laboratory. MICswere determined by the agar dilution method using brain heart infusion agar and Effect of Serum and pH on the In Vitro Potency APR. 1989 The effect of serum and pH on the MICs of pacidamycins 1, 2 and 3 was determined as described previously6). The MICswere determined in the broth containing 50%humanor mouse serum in a microdilution test using Mueller-Hinton broth as the test mediumfor P. aeruginosa A5007 and P. aeruginosa ATCC27853 and brain heart infusion broth for Streptococcus pyogenes 930. The effect of pH on the in vitro potency of pacidamycin 1 was determined by measuring the MICin MuellerHinton broth adjusted to pH 6.5, 7.2 and 8.0.
Time-kill Curves
The kinetics of the bactericidal activity of pacidamycin 1 were determined as described previously^. Four and eight times the MIC of pacidamycin 1 were added to logarithmic phase cultures of P. aeruginosa ATCC27853 grown in Mueller-Hinton broth. Aliquots of the cultures were removed at 30 minutes, 1, 2, 4, 6 and 24 hours and cultured quantitatively to determine the viable bacterial counts.
Resistance Frequency
The frequency of resistance to pacidamycin 1 was determined as described previously70. An 18-hour culture grown from a single colony of P. aeruginosa ATCC27853 was diluted in 10-fold dilutions and plated on Mueller-Hinton agar containing 4 and 8 times the MIC of pacidamycin 1. The stability of resistance in the mutants was determined by serially passing the cultures on antibiotic-free agar and then re-testing the susceptibility of the resistant mutants.
MouseProtection Test
CF-1 female mice (Sasco, Oregon, Wisconsin) were infected intraperitoneally with 1 x 106 cfu of P. aeruginosa A5007 suspended in 5 %hog gastric mucin. The mice were treated subcutaneously with 100, 25 and 6.3 mg/kg/day at 1 and 5 hours after infection and the median effective dose (ED50) was determined on the basis of cumulative mortalities on the 6th day after infection.
Pharmacokinetic Studies The serum and urine concentrations of pacidamycins 1, 2 and 3 were each determined by HPLC after a single dose of 25 mg/kg administered subcutaneously and orally. The chromatograph was comprised of a Waters model 6000A solvent delivery system, Rheodyne model 7125 injector and a Kratos SF 770 UVdetector set at 258 nm. Pacidamycins 1, 2 and 3 were quantitated using the external standards method on a Waters 0.39 x 30 cm^Bondapak TM(C-18, 10^m) column by isocratic elution with CH3CN-0.01 m TFA in ratios of 23:77, 22:78 and 20:80, respectively.
At a flow rate of 1 ml/minute, the retention times for pacidamycins 1, 2 and 3 were 10, 8 and 5 minutes, respectively. Serumsamples were assayed directly, whereasurine sampleswere subjected to solid phase extraction using 3 ml Bond Elut columns (Analytichem). The solid phase extraction procedure consisted of the following steps : 1) Column conditioning in water, 2) sample application, 3) elution with water, 4) elution with 10% methanol and 5) elution of the pacidamycins in 100% methanol. Recovery by this method was 50±4%.
Results
In Vitro Activity The MICsof pacidamycins 1~3 and 5 against a wide variety of bacteria are shown in Table 1 . They have no activity against Gram-positive bacteria, such as Staphylococcus aureus and S. pyogenes, except against Streptococci with the inducible (S. pyogenes 2548) and constitutive-type (S. pyogenes 930) of macrolide resistance. Enterobacteriaceae were not susceptible to 100 //g/ml. The lack of activity against Enterobacteriaceae is probably related to impermeability of the lipopolysaccharide layer to pacidamycins, since Escherichia coli SS, a strain which is deficient in its lipopolysaccharide layer and supersensitive to most classes of antibiotics, is sensitive to the pacidamycins. The pacida- 56  100  100  100  100  100  100  50  50  100  1.56  25  64  64  100  128  128  128  100  128  128   >100  >100  >100  >100  >100  >100  >100  >100  >100  >100  >100  >100  >100  >100  50  >100  >100  6.25  >100  100  >100  >100  >100  >100  50  25  >100  3.12   25  ND  ND  >100  ND  ND  ND  >100 ND ND >100 >100 >100 >100 >100 >100 >100 >100 >100 >100 >100 >100 >100 >100 25 100 >100 6 .25 >100 >100 >100 >100 >100 >100 100 50 >100
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mycins had selective activity against P. aeruginosa. Therefore, the compoundswere tested against a variety of P. aeruginosa using Mueller-Hinton agar as the test medium.The results are shownin Table 2 . Pseudomonas species other than P. aeruginosa were generally resistant to pacidamycins.
Effect of Serum The MICs of pacidamycins 1, 2 and 3 against P. aeruginosa were increased by two to 6-fold by the addition of humanor mouse serum to the medium. The MICswere decreased at least 2-fold when the pacidamycins were tested against S. pyogenes 930 (Table 3) . Effect of pH Pacidamycin 1 was 2-fold more active at pH 6.5 than at pH 7.2. At the basic pH (pH 8.0) pacidamycin 1 was two to 4-fold less active against P. aeruginosa and 2-fold moreactive against S. pyogenes than at pH 7.2 (Table 4) .
Killing Kinetics Pacidamycin 1 was bactericidal at 4 and 8 times the MIC (Fig. 1) . The bacterial counts were reduced by 3 log10 cfu/ml in 4 hours. However, at 24 hours the cultures had re-grown to the same level as the controls. Bacterial colonies isolated from these cultures were resistant to 4 and 8 times the MIC of pacidamycin 1. 
Resistance Frequency
The frequency of resistance of P. aeruginosa ATCC27853 to pacidamycin 1 at 4 times the MIC was 4.4x10"6 and at 8 times the MIC was 3.5xl0~6. The MIC of pacidamycin 1 for P. aeruginosa ATCC27853 was 8^g/ml and the å Gontrol (no antibiotic), à" 64 /ig/ml (4 x MIC), A l28 /xg/ml (8xMIC).
MICsfor the resistant mutants were >32^g/ml. The resistant mutants remained resistant after 10 transfers in antibiotic-free medium. The MICs of piperacillin and gentamicin were the same for the resistant-mutants and the wild-type parent strain suggesting that the mutants had changes in their cell envelope only causing permeation resistance to limited antibiotics such as pacidamycins.
MouseProtection Test
Pacidamycin 1 was inactive in vivo when tested against P. aeruginosa A5007 in mice even after administration of 100 mg/kg/day.
Pharmacokinetics in Mice
The compoundswerenot absorbed after oral administration. After subcutaneous administration of 25 mg/kg, pacidamycins 2 and 3 were not detected in the serum at 30 minutes to 24 hours. The percent urine recoveries were 50.4 for pacidamycin 2 and 32.8 for pacidamycin 3. The peak serum concentration (Cmax) of pacidamycin 1 was 50 jug/ml at 0.5 hour after a single subcutaneous dose of 25 mg/kg. The serum half-life was 0.5 hour and the area under the serum curve was 31.3 /^g-hour/ml. The percent urine recovery was 20%. The reason for not finding pacidamycins 2 and 3 in the serum could be a result of a shorter serum half-life for pacidamycins 2 and 3 relative to pacidamycin 1, since the first determination was at 0.5 hour.
Discussion
Antibiotics which have activity against P. aeruginosa are not commonlyfound in nature. This may be related to the ubiquitous occurrence of this bacteria in our environment and its ability to survive in the environment. Therefore, pacidamycins are unusual antibiotics in having selective activity against P. aeruginosa. The only other organisms that pacidamycins had activity against were S.
pyogenes strains carrying macrolide-lincosamide-streptogramin (MLS)-type resistance. Wedo not APR. 1989 knowwhy pacidamycins have activity against MLS-resistant Streptococci but have no activity against macrolide susceptible Streptococci. Pacidamycin 1 was initially bactericidal, but resistant colonies were soon selected since the frequency of resistance was quite high. The resistant mutants have not been characterized to determine if they were mutants in the peptide transport system. These mutants, however, were stable in the absence of antibiotic and their susceptibility to piperacillin and gentamicin wasthe same as that of the parent strain.
Although pacidamycins are peptide antibiotics, they are relatively stable in serum. However, they were inactive in vivo in mouseprotection tests. Since high serum concentrations were achieved by pacidamycin 1, the lack of in vivo activity is probably related to a combination of factors such as selection of resistant bacteria and also decreased activity of pacidamycin 1 in the presence of serum.
